Clinical trial
A Phase 2, Open-Label, Multi-Center Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in De Novo Bone Marrow Transplant Recipients
NCT00189761 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-Label, Multi-Center Study to Assess Efficacy, Safety and Pharmacokinetics of a Tacrolimus New Oral Formulation (MR4) in De Novo Bone Marrow Transplant Recipients
- Lead sponsor
- Astellas Pharma Inc
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- Not reported
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
bone marrow transplantation, graft versus host disease, graft-versus-host disease, graft-vs-host disease